These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 8423765

  • 1. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK.
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [Abstract] [Full Text] [Related]

  • 2. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1.
    Gallagher EP, Wienkers LC, Stapleton PL, Kunze KL, Eaton DL.
    Cancer Res; 1994 Jan 01; 54(1):101-8. PubMed ID: 8261428
    [Abstract] [Full Text] [Related]

  • 3. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
    Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT.
    J Pharmacol Exp Ther; 1996 May 01; 277(2):685-90. PubMed ID: 8627546
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
    Martínez C, Albet C, Agúndez JA, Herrero E, Carrillo JA, Márquez M, Benítez J, Ortiz JA.
    Clin Pharmacol Ther; 1999 Apr 01; 65(4):369-76. PubMed ID: 10223772
    [Abstract] [Full Text] [Related]

  • 5. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
    Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE.
    J Pharmacol Exp Ther; 1997 Dec 01; 283(3):1552-62. PubMed ID: 9400033
    [Abstract] [Full Text] [Related]

  • 6. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
    Zhang Y, Guo X, Lin ET, Benet LZ.
    Drug Metab Dispos; 1998 Apr 01; 26(4):360-6. PubMed ID: 9531525
    [Abstract] [Full Text] [Related]

  • 7. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
    Danie WA, Syrek M, Ryłko Z, Wójcikowski J.
    Pol J Pharmacol; 2001 Apr 01; 53(4):351-7. PubMed ID: 11990081
    [Abstract] [Full Text] [Related]

  • 8. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
    Wandel C, Lang CC, Cowart DC, Girard AF, Bramer S, Flockhart DA, Wood AJ.
    Clin Pharmacol Ther; 1998 May 01; 63(5):506-11. PubMed ID: 9630823
    [Abstract] [Full Text] [Related]

  • 9. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
    Desta Z, Soukhova N, Mahal SK, Flockhart DA.
    Drug Metab Dispos; 2000 Jul 01; 28(7):789-800. PubMed ID: 10859153
    [Abstract] [Full Text] [Related]

  • 10. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.
    Postlind H, DanielsonA, Lindgren A, Andersson SH.
    Drug Metab Dispos; 1998 Apr 01; 26(4):289-93. PubMed ID: 9531513
    [Abstract] [Full Text] [Related]

  • 11. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
    Kroemer HK, Fischer C, Meese CO, Eichelbaum M.
    Mol Pharmacol; 1991 Jul 01; 40(1):135-42. PubMed ID: 1857335
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M, Shindo M, Shimada T.
    Drug Metab Dispos; 2001 Feb 01; 29(2):200-5. PubMed ID: 11159812
    [Abstract] [Full Text] [Related]

  • 15. N-Dealkylation and hydroxylation of ebastine by human liver cytochrome P450.
    Hashizume T, Mise M, Terauchi Y, O L, Fujii T, Miyazaki H, Inaba T.
    Drug Metab Dispos; 1998 Jun 01; 26(6):566-71. PubMed ID: 9616193
    [Abstract] [Full Text] [Related]

  • 16. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
    Pearce RE, Gotschall RR, Kearns GL, Leeder JS.
    Drug Metab Dispos; 2001 Dec 01; 29(12):1548-54. PubMed ID: 11717173
    [Abstract] [Full Text] [Related]

  • 17. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A.
    Desta Z, Soukhova N, Morocho AM, Flockhart DA.
    J Pharmacol Exp Ther; 2001 Aug 01; 298(2):508-20. PubMed ID: 11454912
    [Abstract] [Full Text] [Related]

  • 18. Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes.
    Abass K, Reponen P, Turpeinen M, Jalonen J, Pelkonen O.
    Drug Metab Dispos; 2007 Sep 01; 35(9):1634-41. PubMed ID: 17576805
    [Abstract] [Full Text] [Related]

  • 19. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone.
    Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M.
    Clin Pharmacol Ther; 1989 Jan 01; 45(1):28-33. PubMed ID: 2910635
    [Abstract] [Full Text] [Related]

  • 20. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD.
    J Pharmacol Exp Ther; 1999 Sep 01; 290(3):1116-25. PubMed ID: 10454485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.